Browsing by Autor "Kavya Remala"

Now showing 1 - 4 of 4

A systematic review and meta-analysis of new-onset atrial fibrillation in the context of COVID-19
(2023) Sawai Singh Rathore; Akanksha Atulkar; Kavya Remala; Vanessa Vidaurre Corrales; Ameer Mustafa Farrukh; Ravinderjeet Kaur Puar; Sem Josue Nsanh Yao; Vijaya Durga Pradeep Ganipineni; Nirmal Patel; Naganath Thota
Background: New-onset atrial fibrillation (NOAF) in COVID-19 raises significant clinical and public health issues. This systematic review and meta-analysis aims to compile and analyze the current literature on NOAF in COVID-19 and give a more comprehensive understanding of the prevalence and outcomes of NOAF in COVID-19. Methods: A comprehensive literature search was carried out using several databases. The random effect model using inverse variance method and DerSimonian and Laird estimator of Tua2 was used to calculate the pooled prevalence and associated 95% confidence interval (CI). Results for outcome analysis were presented as odds ratios (ORs) with 95% CI and pooled using the Mantel-Haenszel random-effects model. Results: The pooled prevalence of NOAF in COVID-19 was 7.8% (95% CI, 6.54% to 9.32%), pooled estimate from 30 articles (81,929 COVID-19 patients). Furthermore, our analysis reported that COVID-19 patients with NOAF had a higher risk of developing severe disease compared with COVID–19 patients without a history of atrial fibrillation (OR= 4.78, 95% CI 3.75 to 6.09) and COVID-19 patients with a history of pre-existing atrial fibrillation (OR= 2.75, 95% CI 2.10 to 3.59) . Similarly, our analysis also indicated that COVID–19 patients with NOAF had a higher risk of all-cause mortality compared with, COVID–19 patients without a history of atrial fibrillation (OOR= 3.83, 95% CI 2.99 to 4.92) and COVID-19 patients with a history of pre-existing atrial fibrillation (OR= 2.32, 95% CI 1.35 to 3.96). The meta-analysis did not reveal any significant publication bias. Conclusion: The results of the current meta-analysis a high prevalence rate of NOAF among COVID-19 patients. Further the study reported higher disease severity with NOAF compared with COVID-19 patients without a history of atrial fibrillation and with a history of atrial fibrillation.
A systematic review and meta‐analysis of new‐onset atrial fibrillation in the context of COVID‐19 infection
(Wiley, 2024) Sawai Singh Rathore; Akanksha Atulkar; Kavya Remala; Vanessa Vidaurre Corrales; Ameer Mustafa Farrukh; Ravinderjeet Kaur Puar; Sem Josue Nsanh Yao; Vijaya Durga Pradeep Ganipineni; Nirmal Patel; Naganath Thota
New-onset atrial fibrillation (NOAF) in COVID-19 raises significant clinical and public health issues. This systematic review and meta-analysis aims to compile and analyze the current literature on NOAF in COVID-19 and give a more comprehensive understanding of the prevalence and outcomes of NOAF in COVID-19. A comprehensive literature search was carried out using several databases. The random effect model using inverse variance method and DerSimonian and Laird estimator of Tua2 was used to calculate the pooled prevalence and associated 95% confidence interval (CI). Results for outcome analysis were presented as odds ratios (ORs) with 95% CI and pooled using the Mantel-Haenszel random-effects model. The pooled prevalence of NOAF in COVID-19 was 7.8% (95% CI: 6.54%-9.32%),a pooled estimate from 30 articles (81 929 COVID-19 patients). Furthermore, our analysis reported that COVID-19 patients with NOAF had a higher risk of developing severe disease compared with COVID-19 patients without a history of atrial fibrillation (OR = 4.78, 95% CI: 3.75-6.09) and COVID-19 patients with a history of pre-existing atrial fibrillation (OR = 2.75, 95% CI: 2.10-3.59). Similarly, our analysis also indicated that COVID-19 patients with NOAF had a higher risk of all-cause mortality compared with, COVID-19 patients without a history of atrial fibrillation (OR = 3.83, 95% CI: 2.99-4.92) and COVID-19 patients with a history of pre-existing atrial fibrillation (OR = 2.32, 95% CI: 1.35-3.96). The meta-analysis did not reveal any significant publication bias. The results indicate a strong correlation between NOAF and a higher risk of severe illness and mortality. These results emphasize the importance of careful surveillance, early detection, and customized NOAF management strategies to improve clinical outcomes for COVID-19 patients.
Risk of cardiovascular events among celiac disease patients: A meta-analysis review
(Biomedical Informatics, 2025) Saad Shams; Vanessa Vidaurre Corrales; Ibrahim Marouf Yasin Al Shyyab; Akshat Banga; Ameer Mustafa Farrukh; Moza A Alzaabi; Majd Atef Albeetar; Sem Josue Nsanh Yao; Kavya Remala; M. Mahfouz
A review on the association between celiac disease and cardiovascular events using multiple databases and random effects models is of interest. The overall prevalence of cardiovascular events in celiac patients was 9.3%. However, there was no significant increase in overall cardiovascular risk or myocardial infarction compared to the general population. Known data shows that celiac disease was linked to a higher risk of atrial fibrillation, stroke, congestive heart failure and cardiomyopathy. Thus, there is a need to monitor cardiovascular health in celiac patients to mitigate potential risks.
Unveiling the Dual Threat: Myocarditis in the Spectrum of Dengue Fever
(Elsevier BV, 2023) Ameer Mustafa Farrukh; Vijaya Durga Pradeep Ganipineni; Urmi Jindal; Abhishek Chaudhary; Ravinderjeet Kaur Puar; Klodin Ghazarian; Vanessa Vidaurre Corrales; S. Alarcón; Kavya Remala; Naganath Thota